Navigation Links
Nutrastar Announces Second Quarter 2011 Financial Results
Date:8/12/2011

od in 2010. For the six months ended June 30, 2011, income before income tax increased $2.07 million, or 29.2%, to $9.15 million from $7.08 million incurred in the comparable 2010 period. Income before income tax as a percentage of revenues decreased to 67.9% in the six months ended June 30, 2011 from 69.2% recorded in the same six month 2010 period. The decrease of income before income tax as a percentage of revenues is mainly attributable to the increase in costs associated with the production of our functional health beverages and an increase in selling and general and administrative expenses, which outpaced the increase in our total revenues during both the three months and six months ended June 30, 2011. The increase in selling expenses was mainly attributable to the selling and marketing expenses incurred in the rollout of our functional health beverages to additional distribution channels and costs associated with opening of the Company's specialty stores. The increase in general and administrative expenses was mainly due to increased remuneration to our management and service providers.

Net Income

Net income increased by $0.49 million, or 14.2% to $3.90 million for the three months ended June 30, 2011 from $3.42 million for the same period of 2010. For the six months ended June 30, 2011, net income increased by $0.77 million, or 12.6% to $6.91 million from $6.14 million for the same period of 2010.

Earnings Per Share

Basic and diluted EPS for the three months ended June 30, 2011 was $0.26 and $0.24, based on 14.79 million and 16.39 million shares outstanding, respectively, an increase of $0.14 or 116.7% in basic EPS and $0.12 or 100% in diluted EPS from the same period in 2010 when there were approximately 14.33 million basic and 14.34 million diluted shares outstanding. For the six months ended June 30, 2011, basic and diluted EPS was $0.46 and $0.42, based on 14.64 million and 16.31 million shares outstanding, resp
'/>"/>

SOURCE Nutrastar International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Nutrastar to Present at the Upcoming 2011 Global Hunter Securities Conference
2. Nutrastar to Participate in Brean Murray, Carret & Co.s 2011 Beijing China Growth Conference
3. Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details
4. Nutrastar Distribution Spreads into Anhui Province
5. Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011
6. Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC
7. Echo Therapeutics Announces Second Quarter 2011 Financial Results
8. ShangPharma Announces Up to $10 Million Share Repurchase Program
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 20, 2011 and to Provide a Business Update
10. DMES, Inc. Announces 100 Percent Growth for Online Medical Supply Store
11. China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... SPRINGS, Colo. , Aug. 22, 2014 /PRNewswire/ ... specializing in cannabis formulation-based drug development and related ... UFCM iCare,s third international medical cannabis conference taking ... Strasbourg, France , on October 22, ... with other stakeholders, such as researchers, health professionals, ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... -- Phase II,results exceed expectations - Alchemia prepares ... company Alchemia Limited will,commence discussions with the US ... of the Phase II clinical trial,of its metastatic ... from the randomized Phase II clinical trial in ...
... data on Eloxatin(R), Taxotere(R) and on three investigational,agents ... at the 43rd,annual ASCO meeting, BRIDGEWATER, N.J., May ... total of 375 abstracts,indicative of its oncology commitment ... the American Society of Clinical Oncology,(ASCO) in Chicago, ...
Cached Medicine Technology:Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 2Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 3Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:8/23/2014)... (PRWEB) August 23, 2014 Having been in ... dental hygienist from Arlington, Texas, saw a need for an ... toothpaste. "That’s when I came up with the idea for ... provides an effective way for a user to clean the ... to carry multiple items. It also helps avoid plaque buildup ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Hundreds ... filed on behalf of individuals who were allegedly ... replacement line continue to move forward in the ... Liebhard LLP reports. According to an Order dated ... trial program that would allow the litigation’s first ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Youth substance abuse is a serious problem across ... TX. Substance abuse can happen to people of all ... dependency in higher numbers than ever before. Many ... don’t know where to find professional youth rehab. ... because most treatment options are designed for adults. The ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... Md., May 8 Micromet, Inc. (Nasdaq:,MITI), a biopharmaceutical ... the treatment of cancer, inflammation and,autoimmune diseases, today announced ... 2008., Summary of Recent Events:, -- ... phase 1 clinical trial with ...
... Sciences,Inc. (Nasdaq: HGSI ) today announced that John ... of Pfizer Global Research and,Development, has been appointed to ... ), "We are honored to have John ... President and Chief Executive Officer, HGS. "John,s,record of accomplishment ...
... Ortho Organizers, Inc., a,leading manufacturer of orthodontic ... of their new premium O2 Select Orthodontic,Instruments., ... Organizers President and CEO George W. Guttroff ... with the release of O2 Select,Orthodontic Instruments. ...
... than $8 million for medicines and other lifesaving ... ... death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely concerned that the ... increase the death toll among children and other,vulnerable populations, leading to a ...
... Calif., May 8 Samplify Systems, Inc., a,real-time ... Crawford, a leading expert in computed tomography, has ... of experience in the,architecture, design, and development of ... "We are delighted to add Carl,s knowledge of ...
... Hospital buildings can heal,according to the first ... the,physical environment on child patients in health care ... through the,Physical Environment is produced by the National ... partnership with the Center,for Health Design. Findings from ...
Cached Medicine News:Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2008 Financial Results 9Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 2Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 3Health News:Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors 4Health News:Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments 2Health News:Myanmar Cyclone a Children's Catastrophe - UNICEF 2Health News:Samplify Systems Adds Computed Tomography Expert Carl Crawford to Technical Team 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 2Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 3Health News:Hospital Buildings Can Heal According to First Comprehensive Report on Impact of Physical Environment on Child Patients 4
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: